Neurogene Inc.
NGNE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404644
In the last 90 days, Neurogene Inc. insiders filed 0 open-market purchases and 2 sales; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Neurogene Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- +17 vs. Q1 2026
- Shares held
- 17.3M
- +343.6K (+2.0%) vs. Q1 2026
- Total value
- $544.4M
- +$202.5M (+59.2%) vs. Q1 2026
- New holders
- 21
- 38 more added
- Sold out
- 4
- 31 more reduced
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NGNE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 111 | $544.4M |
| Q1 2026 | 96 | $342.0M |
| Q4 2025 | 93 | $340.4M |
| Q3 2025 | 88 | $265.2M |
| Q2 2025 | 83 | $230.1M |
| Q1 2025 | 86 | $192.8M |
| Q4 2024 | 89 | $367.8M |
| Q3 2024 | 86 | $581.1M |
| Q2 2024 | 66 | $482.7M |
| Q1 2024 | 60 | $617.3M |
| Q4 2023 | 35 | $179.0M |
| Q3 2023 | 31 | $14.4M |
| Q2 2023 | 36 | $14.3M |
| Q1 2023 | 39 | $10.5M |
| Q4 2022 | 46 | $8.66M |
| Q3 2022 | 52 | $12.0M |
| Q2 2022 | 64 | $21.4M |
| Q1 2022 | 81 | $46.3M |
| Q4 2021 | 80 | $118.8M |
| Q3 2021 | 85 | $187.1M |
| Q2 2021 | 82 | $248.8M |
| Q1 2021 | 82 | $341.9M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Neurogene Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 536,525 | $16.9M | 0.00% | +21,798+4.2% | Added |
| Toronto Dominion Bank | 681,337 | $21.4M | 0.04% | 00.0% | Unchanged |
| Trails Edge Capital Partners, LP | 714,885 | $22.5M | 3.57% | −67,902−8.7% | Reduced |
| Balyasny Asset Management LLC | 818,706 | $25.7M | 0.05% | +100,317+14.0% | Added |
| Baker Bros. Advisors LP | 991,691 | $31.2M | 0.16% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,057,983 | $33.3M | 0.00% | +52,913+5.3% | Added |
| EcoR1 Capital, LLC | 1,271,342 | $40.0M | 1.98% | 00.0% | Unchanged |
| RTW Investments, LP | 1,362,456 | $42.8M | 0.37% | 00.0% | Unchanged |
| Redmile Group, LLC | 1,412,199 | $44.4M | 2.98% | −47,400−3.2% | Reduced |
| Casdin Capital, LLC | 1,545,361 | $48.6M | 2.43% | +125,000+8.8% | Added |
| Samsara BioCapital, LLC | 1,717,127 | $54.0M | 4.44% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −13,891−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −12,724−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −89−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| CWM, LLC | – | – | – | – | Not filed |
| Sunbelt Securities, Inc. | – | – | – | – | Not filed |